Roles of Whole-Genome Sequencing in Determining Transmission and Risk Factors Associated with Carbapenem-Resistant Organisms at a Vietnam HealthCare Center of Orphan Children
Abstract
:1. Introduction
- (1)
- to determine the prevalence of CRO colonization in HCWs, residents, and the environment;
- (2)
- to determine the CRO contamination/transmission between HCWs and residents; and
- (3)
- to show the risk factors of CRO colonization in HCWs and residents in this center.
2. Materials and Methods
2.1. Definitions
2.2. Design
2.3. Sample Collection
- Open the swab package and remove a sampling swab tube from this package.
- Then, hold the tube cap, and remove a cotton swab stick inside. Only touch the cap.
- Do not touch a cotton swab stick. Insert a sterile rectal cotton sampling swab approximately 1 cm into the anal canal.
- Then, rotate slowly for 10 s. Take the amount of feces collected on a cotton swab that is enough to perform the appropriate microbiological tests.
- Next, put the rectal swab specimens into the Amies-Transport Medium.
- Finally, these fecal specimens must be stored in a container with dry ice and transported to the Lab Department of Hung Vuong Hospital as soon as possible within 6 h after collecting rectal swab specimens.
- The sterile rectal cotton sampling swab was a tool used to collect the environmental sample.
- An approximate area (10 × 10 cm) of environmental surfaces or furnishings was a standard for collecting environmental samples. After that, they were put into the Amies Transport Medium, stored in a container with dry ice, and transported to the Lab Department of Hung Vuong Hospital as soon as possible, within 6 h after sample collection (Figure 1).
2.4. Microbiology Methods
2.5. Whole-Genome Sequencing (WGS)
2.6. At Charles River Laboratories in Australia: Process of Performing WGS
2.7. Statistical Analysis
3. Results
3.1. Results of Whole-Genome Sequencing of 12 CROs Analyzed at Charles River Laboratories in Australia
- (1)
- There might be some infections due to transmission/contamination events within an orphanage.
- (2)
- Antibiotic profiling of these isolates demonstrated high resistance.
- ▪
- 80% (20/25) between E. coli of C4003 (6276066) and H006 (6276065);
- ▪
- 92% (23/25) between A. baumannii of C3022 (6276070) and H009 (6276073);
- ▪
- 92% (23/25) between A. baumannii of C3011 (6276071) and H009 (6276073);
- ▪
- 100% (25/25) between A. baumannii of C3022 (6276070) and C3011 (6276071).
3.2. Transmission/Contamination Tracking by SNP (Single-Nucleotide Polymorphism) Count
3.2.1. Transmission/Contamination Between the Isolates, Including 6276070, 6276071, and 6276073_Isolate
3.2.2. Transmission/Contamination Between the Isolates, Including the 6276065, 6276066 Isolates
- (1)
- between the 6276070 (C3022), 6276071 (C3011), and 6276073 (H009) isolate;
- (2)
- between the 6276065 (H006) and 6276066 (C4003) isolate.
3.3. Prevalence of CROs in HCWs, Residents, and Environment
3.4. Characteristics (Demographics) of Independent Variables Associated with HCWs and Residents
3.4.1. Demographic Characteristics of HCWs and Residents
3.4.2. Demographic Characteristics of HCWs and Residents Related to Antibiotic Use
3.4.3. Demographic Characteristics of HCWs and Residents Related to Length of Hospital Stay and Number of Hospital Admission Times
3.4.4. Demographic Characteristics of HCWs and Children Related to Procedures Performed on HCWs and Residents
3.5. Risk Factors Associated with CROs in HCWs and Residents
- CRO-transmission events between HCWs and residents: one case of E. coli transmission was between an HCW (H006) and one resident, a child (C4003), and another case of A. nosocomialis transmission between an HCW (H009), and two residents (C3022 and (C3011), who were children.
- In twelve CRO isolates detected in 11 participants, we detected two CREs, including one E. coli and one K pneumonia isolate colonized in a child (C4003).
- A total of 11 participants included five HCWs: H006, H007, H008, and H009 working in the first floor and H019 working in both the general and first floor. Five of six residents have resided on the first floor and one (C3002) on the general floor, as described in Table 2 and Table 4. HCWs participating in performing the WGS were the child carers shown in Table S2 (Supplementary Tables).
- The age of all residents was less than 27 years old.
- Residents have lived together in the Center of Care and Protection of Orphan Children for a long time. So, residents have spent a long duration in close contact between themselves and between them and HCWs.
- The study group included 87 participants (20 HCWs and 67 residents) in a unity group. This data suggested risk factors can occur when HCWs and residents have worked and resided for a long time in the Center of Care and Protection of Orphan Children. Additionally, there have been a lot of occasions for interaction between HCWs and residents during long-term care or treatment. All factors can contribute to developing the risk factors of CRO contamination.
- The CRO colonization was due to the association of two or many characteristics activating together, for instance, an age higher than 27 years old and working or residing in the Center of Care and Protection of Orphan Children for more than four years, etc.
- We divided 87 participants into two sub-groups: one belongs to the HCW sub-group, and another belongs to the resident subgroup, based on a 27-year-old value (Table 5).
3.5.1. Risk Factors Associated with CROs in a Group, Including HCWs and Residents
3.5.2. Risk Factors Associated with CROs in Two Different Groups, Including HCWs and Residents
4. Discussion
5. Conclusions
6. Limitation of Study
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations and Acronyms
1. Abbreviations of antibiotics | ||
AK: Amikacin; | CRO: Ceftriaxone; | NOR: Norfloxacin; |
AM: Ampicillin; | CXM: Cefuroxime; | TZP: Piperacillin/tazobactam; |
AMC: Amoxicillin-clavulanic acid; | CIP: Ciprofloxacin, | TGC: Tigecylin; |
AZM: Aztreonam; | CST: Colistin; | SXT: Trimethoprim-sulphamethoxazole; |
CZ: Cefazolin; | FO: Fosfomycin; | I: Intermediate; |
FEP: Cefepime; | GEN: Gentamicin; | R: Resistance; |
FOX: Cefoxitin; | LVX: Levofloxacin; | X: MICs of antibiotics are in the range of sensitive or intermediate; |
CAZ: Ceftazidime; | MIN: Minocycline; | N: is an antibiotic not recommended for the treatment of infections; |
CZA: Ceftazidime/avibactam; | NFN: Nitrofurantoin. | |
2. Abbreviations related to study | ||
ANI: Average nucleotide identity | B. cepacia: Burkholderia cepacia | |
CPE: Carbapenemase-producing Enterobacteriaceae; | A. baumannii: Acinetobacter baumannii: | |
CPO: Carbapenemase-producing organisms; | A. faecalis: Alcaligenes faecalis; | |
CRE: Carbapenem-resistant Enterobacteriaceae; | E. cloacae: Enterobacter cloacae; | |
CRO: Carbapenem-resistant organisms; | E. coli: Escherichia coli; | |
ESBL: Extended-spectrum β-lactamase; | K. pneumoniae: Klebsiella pneumoniae | |
HCW: Healthcare Workers; | P. aeruginosa: Pseudomonas aeruginosa ; | |
HCP: Healthcare personnel; | P. putida: Pseudomonas putida | |
NICU: Neonatal Intensive Care Unit; | S. maltophilia: Stenotrophomonas maltophilia; | |
PICU: Pediatric Intensive Care Unit | ||
SICU: Surgical Intensive Care Unit | ||
SNP: Single nucleotide polymorphism; | ||
WGS: Whole-Genome Sequencing |
References
- WHO. Antimicrobial Resistance Global Report on Surveillance: 2014 Summary. 2014. Available online: https://www.who.int/publications/i/item/WHO-HSE-PED-AIP-2014.2 (accessed on 23 November 2024).
- CDC. ANTIBIOTIC RESISTANCE THREATS in the United States, 2013. 2013. Available online: https://www.cdc.gov/antimicrobial-resistance/media/pdfs/ar-threats-2013-508.pdf (accessed on 23 November 2024).
- Public Health Agency of Canada. Antimicrobial resistance and use in Canada: A federal framework for action. Can. Commun. Dis. Rep. 2014, 40, 2–5. [Google Scholar] [CrossRef] [PubMed]
- European Centre for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe 2015; Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net); ECDC: Stockholm, Sweden, 2017; Available online: https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2015 (accessed on 23 November 2024).
- Nordmann, P.; Poirel, L. Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. Clin. Infect. Dis. 2019, 69, S521–S528. [Google Scholar] [CrossRef]
- Tacconelli, E.; Carrara, E.; Savoldi, A.; Harbarth, S.; Mendelson, M.; Monnet, D.L.; Pulcini, C.; Kahlmeter, G.; Kluytmans, J.; Carmeli, Y.; et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 2018, 18, 318–327. [Google Scholar] [CrossRef] [PubMed]
- Peleg, A.Y.; Hooper, D.C. Hospital-acquired infections due to gram-negative bacteria. New Engl. J. Med. 2010, 362, 1804–1813. [Google Scholar] [CrossRef] [PubMed]
- Giakkoupi, P.; Papagiannitsis, C.C.; Miriagou, V.; Pappa, O.; Polemis, M.; Tryfinopoulou, K.; Tzouvelekis, L.S.; Vatopoulos, A.C. An update of the evolving epidemic of blaKPC-2-carrying Klebsiella pneumoniae in Greece (2009-10). J. Antimicrob. Chemother. 2011, 66, 1510–1513. [Google Scholar] [CrossRef]
- Porres-Osante, N.; Azcona-Gutiérrez, J.M.; Rojo-Bezares, B.; Undabeitia, E.; Torres, C.; Sáenz, Y. Emergence of a multiresistant KPC-3 and VIM-1 carbapenemase-producing Escherichia coli strain in Spain. J. Antimicrob. Chemother. 2014, 69, 1792–1795. [Google Scholar] [CrossRef]
- Reyes, J.A.; Melano, R.; Cárdenas, P.A.; Trueba, G. Mobile genetic elements associated with carbapenemase genes in South American Enterobacterales. Braz. J. Infect. Dis. 2020, 24, 231–238. [Google Scholar] [CrossRef]
- Harris, A.D.; Kotetishvili, M.; Shurland, S.; Johnson, J.A.; Morris, J.G.; Nemoy, L.L.; Johnson, J.K. How important is patient-to-patient transmission in extended-spectrum beta-lactamase Escherichia coli acquisition. Am. J. Infect. Control 2007, 35, 97–101. [Google Scholar] [CrossRef]
- Harris, A.D.; Perencevich, E.N.; Johnson, J.K.; Paterson, D.L.; Morris, J.G.; Strauss, S.M.; Johnson, J.A. Patient-to-patient transmission is important in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae acquisition. Clin. Infect. Dis. 2007, 45, 1347–1350. [Google Scholar] [CrossRef]
- Adler, A.; Navon-Venezia, S.; Moran-Gilad, J.; Marcos, E.; Schwartz, D.; Carmeli, Y. Laboratory and clinical evaluation of screening agar plates for detection of carbapenem-resistant Enterobacteriaceae from surveillance rectal swabs. J. Clin. Microbiol. 2011, 49, 2239–2242. [Google Scholar] [CrossRef]
- Kochar, S.; Sheard, T.; Sharma, R.; Hui, A.; Tolentino, E.; Allen, G.; Landman, D.; Bratu, S.; Augenbraun, M.; Quale, J. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 2009, 30, 447–452. [Google Scholar] [CrossRef] [PubMed]
- Enfield, K.B.; Huq, N.N.; Gosseling, M.F.; Low, D.J.; Hazen, K.C.; Toney, D.M.; Slitt, G.; Zapata, H.J.; Cox, H.L.; Lewis, J.D.; et al. Control of simultaneous outbreaks of carbapenemase-producing enterobacteriaceae and extensively drug-resistant Acinetobacter baumannii infection in an intensive care unit using interventions promoted in the Centers for Disease Control and Prevention 2012 carbapenemase-resistant Enterobacteriaceae Toolkit. Infect. Control Hosp. Epidemiol. 2014, 35, 810–817. [Google Scholar] [CrossRef] [PubMed]
- Chen, X.; Zhou, M.; Yan, Q.; Jian, Z.; Liu, W.; Li, H. Risk factors for carbapenem-resistant Enterobacterales infection among hospitalized patients with previous colonization. J. Clin. Lab. Anal. 2022, 36, e24715. [Google Scholar] [CrossRef]
- Kaye, K.S.; Cosgrove, S.; Harris, A.; Eliopoulos, G.M.; Carmeli, Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob. Agents Chemother. 2001, 45, 2628–2630. [Google Scholar] [CrossRef] [PubMed]
- Zhu, W.M.; Yuan, Z.; Zhou, H.Y. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection relative to two types of control patients: A systematic review and meta-analysis. Antimicrob. Resist. Infect. Control 2020, 9, 23. [Google Scholar] [CrossRef] [PubMed]
- Harris, A.D.; Smith, D.; Johnson, J.A.; Bradham, D.D.; Roghmann, M.C. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin. Infect. Dis. 2002, 34, 340–345. [Google Scholar] [CrossRef]
- Dizbay, M.; Tunccan, O.G.; Sezer, B.E.; Hizel, K. Nosocomial imipenem-resistant Acinetobacter baumannii infections: Epidemiology and risk factors. Scand. J. Infect. Dis. 2010, 42, 741–746. [Google Scholar] [CrossRef]
- Yigit, H.; Queenan, A.M.; Anderson, G.J.; Domenech-Sanchez, A.; Biddle, J.W.; Steward, C.D.; Alberti, S.; Bush, K.; Tenover, F.C. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2001, 45, 1151–1161. [Google Scholar] [CrossRef]
- Palacios-Baena, Z.R.; Giannella, M.; Manissero, D.; Rodríguez-Baño, J.; Viale, P.; Lopes, S.; Wilson, K.; McCool, R.; Longshaw, C. Risk factors for carbapenem-resistant Gram-negative bacterial infections: A systematic review. Clin. Microbiol. Infect. 2021, 27, 228–235. [Google Scholar] [CrossRef]
- Hsu, L.Y.; Apisarnthanarak, A.; Khan, E.; Suwantarat, N.; Ghafur, A.; Tambyah, P.A. Carbapenem-Resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. Clin. Microbiol. Rev. 2017, 30, 1–22. [Google Scholar] [CrossRef]
- Tran, H.D.; Bach Nguyen, Y.T.; Thanh Tran, T.; Thu Le, T.T.; Thu Nguyen, H.T.; Minh Nguyen, C.; Bach Le, H.T.; Ngoc Phan, T.T.; Thanh Vo, T.T.; Ngoc Bui, H.T.; et al. Community-acquired pneumonia-causing bacteria and antibiotic resistance rate among Vietnamese patients: A cross-sectional study. Medicine 2022, 101, e30458. [Google Scholar] [CrossRef]
- Le, N.K.; Hf, W.; Vu, P.D.; Khu, D.T.K.; Le, H.T.; Hoang, B.T.N.; Vo, V.T.; Lam, Y.M.; Vu, D.T.V.; Nguyen, T.H.; et al. High prevalence of hospital-acquired infections caused by gram-negative carbapenem resistant strains in Vietnamese pediatric ICUs: A multi-centre point prevalence survey. Medicine 2016, 95, e4099. [Google Scholar] [CrossRef] [PubMed]
- Price, J.R.; Didelot, X.; Crook, D.W.; Llewelyn, M.J.; Paul, J. Whole genome sequencing in the prevention and control of Staphylococcus aureus infection. J. Hosp. Infect. 2013, 83, 14–21. [Google Scholar] [CrossRef] [PubMed]
- Eyre, D.W. Infection prevention and control insights from a decade of pathogen whole-genome sequencing. J. Hosp. Infect. 2022, 122, 180–186. [Google Scholar] [CrossRef] [PubMed]
- Gniadek, T.J.; Carroll, K.C.; Simner, P.J. Carbapenem-Resistant Non-Glucose-Fermenting Gram-Negative Bacilli: The Missing Piece to the Puzzle. J. Clin. Microbiol. 2016, 54, 1700–1710. [Google Scholar] [CrossRef]
- Israel, G.D. Determining Sample Size; Institute of Food and Agricultural Sciences (IFAS), University of Florida: Gainesville, FL, USA, 1992; Available online: https://www.gjimt.ac.in/web/wp-content/uploads/2017/10/2_Glenn-D.-Israel_Determining-Sample-Size.pdf (accessed on 8 December 2024).
- Lee, I.; Ouk Kim, Y.; Park, S.C.; Chun, J. OrthoANI: An improved algorithm and software for calculating average nucleotide identity. Int. J. Syst. Evol. Microbiol. 2016, 66, 1100–1103. [Google Scholar] [CrossRef]
- Read, A.F.; Woods, R.J. Antibiotic resistance management. Evol. Med. Public Health 2014, 2014, 147. [Google Scholar] [CrossRef]
- Sedláková, M.H.; Urbánek, K.; Vojtová, V.; Suchánková, H.; Imwensi, P.; Kolář, M. Antibiotic consumption and its influence on the resistance in Enterobacteriaceae. BMC Res. Notes 2014, 7, 454. [Google Scholar] [CrossRef]
- Lee, H.S.; Loh, Y.X.; Lee, J.J.; Liu, C.S.; Chu, C. Antimicrobial consumption and resistance in five Gram-negative bacterial species in a hospital from 2003 to 2011. J. Microbiol. Immunol. Infect. 2015, 48, 647–654. [Google Scholar] [CrossRef]
- Moghnieh, R.; Abdallah, D.; Jadayel, M.; Zorkot, W.; El Masri, H.; Dib, M.J.; Omar, T.; Sinno, L.; Lakkis, R.; Jisr, T. Epidemiology, risk factors, and prediction score of carbapenem resistance among inpatients colonized or infected with 3rd generation cephalosporin resistant Enterobacterales. Sci. Rep. 2021, 11, 14757. [Google Scholar] [CrossRef]
- Wilson, G.M.; Suda, K.J.; Fitzpatrick, M.A.; Bartle, B.; Pfeiffer, C.D.; Jones, M.; Rubin, M.A.; Perencevich, E.; Evans, M.; Evans, C.T. Risk Factors Associated with Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Positive Cultures in a Cohort of US Veterans. Clin. Infect. Dis. 2021, 73, 1370–1378. [Google Scholar] [CrossRef]
- Lin, J.L.; Van Haren, K.; Rigdon, J.; Saynina, O.; Song, H.; Buu, M.C.; Thakur, Y.; Srinivas, N.; Asch, S.M.; Sanders, L.M. Pneumonia Prevention Strategies for Children with Neurologic Impairment. Pediatrics 2019, 144, e20190543. [Google Scholar] [CrossRef]
- Allen, J.; Brenner, M.; Hauer, J.; Molloy, E.; McDonald, D. Severe Neurological Impairment: A delphi consensus-based definition. Eur. J. Paediatr. Neurol. 2020, 29, 81–86. [Google Scholar] [CrossRef] [PubMed]
- Çokyaman, T.; Kasap, T.; Çelik, T. Accompanying Infections in Hospitalized Children with Neurological Disease. J. Curr. Pediatr. 2022, 20, 17–26. [Google Scholar] [CrossRef]
- Schechner, V.; Kotlovsky, T.; Kazma, M.; Mishali, H.; Schwartz, D.; Navon-Venezia, S.; Schwaber, M.J.; Carmeli, Y. Asymptomatic rectal carriage of blaKPC producing carbapenem-resistant Enterobacteriaceae: Who is prone to become clinically infected? Clin. Microbiol. Infect. 2013, 19, 451–456. [Google Scholar] [CrossRef] [PubMed]
- Correa, L.; Martino, M.D.; Siqueira, I.; Pasternak, J.; Gales, A.C.; Silva, C.V.; Camargo, T.Z.; Scherer, P.F.; Marra, A.R. A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect. Dis. 2013, 13, 80. [Google Scholar] [CrossRef]
- Feldman, N.; Adler, A.; Molshatzki, N.; Navon-Venezia, S.; Khabra, E.; Cohen, D.; Carmeli, Y. Gastrointestinal colonization by KPC-producing Klebsiella pneumoniae following hospital discharge: Duration of carriage and risk factors for persistent carriage. Clin. Microbiol. Infect. 2013, 19, E190–E196. [Google Scholar] [CrossRef]
- Duong, B.T.; Duong, M.C.; Campbell, J.; Nguyen, V.M.H.; Nguyen, H.H.; Bui, T.B.H.; Nguyen, V.V.C.; McLaws, M.L. Antibiotic-Resistant Gram-negative Bacteria Carriage in Healthcare Workers Working in an Intensive Care Unit. Infect. Chemother. 2021, 53, 546–552. [Google Scholar] [CrossRef]
- Majumdar, S.; Kirby, A.; Berry, N.; Williams, C.; Hassan, I.; Eddleston, J.; Burnie, J.P. An outbreak of imipenem-resistant Pseudomonas aeruginosa in an intensive care unit. J. Hosp. Infect. 2004, 58, 160–161. [Google Scholar] [CrossRef]
- Ambrogi, V.; Cavalié, L.; Mantion, B.; Ghiglia, M.J.; Cointault, O.; Dubois, D.; Prère, M.F.; Levitzki, N.; Kamar, N.; Malavaud, S. Transmission of metallo-β-lactamase-producing Pseudomonas aeruginosa in a nephrology-transplant intensive care unit with potential link to the environment. J. Hosp. Infect. 2016, 92, 27–29. [Google Scholar] [CrossRef]
- Landelle, C.; Legrand, P.; Lesprit, P.; Cizeau, F.; Ducellier, D.; Gouot, C.; Bréhaut, P.; Soing-Altrach, S.; Girou, E.; Brun-Buisson, C. Protracted outbreak of multidrug-resistant Acinetobacter baumannii after intercontinental transfer of colonized patients. Infect. Control Hosp. Epidemiol. 2013, 34, 119–124. [Google Scholar] [CrossRef] [PubMed]
- Abdel Rahman, A.T.; Hafez, S.F.; Abdelhakam, S.M.; Ali-Eldin, Z.A.; Esmat, I.M.; Elsayed, M.S.; Aboul-Fotouh, A. Antimicrobial resistant bacteria among health care workers in intensive care units at Ain Shams University Hospitals. J. Egypt. Soc. Parasitol. 2010, 40, 71–83. [Google Scholar] [PubMed]
- March, A.; Aschbacher, R.; Pagani, E.; Sleghel, F.; Soelva, G.; Hopkins, K.L.; Doumith, M.; Innocenti, P.; Burth, J.; Piazzani, F.; et al. Changes in colonization of residents and staff of a long-term care facility and an adjacent acute-care hospital geriatric unit by multidrug-resistant bacteria over a four-year period. Scand. J. Infect. Dis. 2014, 46, 114–122. [Google Scholar] [CrossRef]
- Adler, A.; Baraniak, A.; Izdebski, R.; Fiett, J.; Salvia, A.; Samso, J.V.; Lawrence, C.; Solomon, J.; Paul, M.; Lerman, Y.; et al. A multinational study of colonization with extended spectrum β-lactamase-producing Enterobacteriaceae in healthcare personnel and family members of carrier patients hospitalized in rehabilitation centres. Clin. Microbiol. Infect. 2014, 20, O516–O523. [Google Scholar] [CrossRef] [PubMed]
- Decker, B.K.; Lau, A.F.; Dekker, J.P.; Spalding, C.D.; Sinaii, N.; Conlan, S.; Henderson, D.K.; Segre, J.A.; Frank, K.M.; Palmore, T.N. Healthcare personnel intestinal colonization with multidrug-resistant organisms. Clin. Microbiol. Infect. 2018, 24, e81–e82. [Google Scholar] [CrossRef] [PubMed]
Part (a): Information of 12 CROs Sent to Charles River Laboratories | ||||
---|---|---|---|---|
No. | Client ID | Location of Work/Residence | Name of CROs with BD Identified in VN | WGS Code in Charles River Laboratories |
1 | 24 (C4 003) | Floor 1 | K. pneumoniae | 6276063 |
2 | 193 (H 019) | Floor 1 and General floor | E. coli (class B) | 6276064 |
3 | 250 (H 006) | Floor 1 | E. coli (class D) | 6276065 |
4 | 251 (C4 003) | Floor 1 | E. coli (class D) | 6276066 |
5 | 256 (C3 002) | General floor | A. baumannii | 6276067 |
6 | 301 (H 008) | Floor 1 | E. cloacae | 6276068 |
7 | 391 (C2 012) | Floor 1 | A. baumannii | 6276069 |
8 | 403 (C3 022) | Floor 1 | A. baumannii | 6276070 |
9 | 413 (C3 011) | Floor1 | A. baumannii | 6276071 |
10 | 414 (C2 020) | Floor 1 | A. baumannii | 6276072 |
11 | 419 (H 009) | Floor 1 | A. baumannii | 6276073 |
12 | H007 (H007) | Floor 1 | E. coli | 6276074 |
Part (b): Genome Assembly Based on Species Identification with WGS at Charles River Laboratories in Australia | ||||
Before WGS performance | After WGS performance | |||
No. | CROs Confirmed with BDAMS in VN | WGS Code | Identification of Provisional Species Before and After WGS. | |
1 | K. pneumoniae | 6276063 | K. pneumoniae | |
2 | E. coli (class B) | 6276064 | E. coli | |
3 | E. coli (class D) | 6276065 | E. coli | |
4 | E. coli (class D) | 6276066 | E. coli | |
10 | A. baumannii | 6276072 | A. baumannii | |
12 | E. coli | 6276074 | E. coli | |
7 | A. baumannii | 6276069 | A. baumannii | |
No. | CROs Confirmed ith BDAMS in VN | WGS Code | Provisional Species Changed after WGS | |
5 | A. baumannii | 6276067 | A. seifertii | |
6 | E. cloacea | 6276068 | E. cloacae/hormaechei | |
8 | A. baumannii | 6276070 | Acinetobacter nosocomialis | |
9 | A. baumannii | 6276071 | Acinetobacter nosocomialis | |
11 | A. baumannii | 6276073 | A. baumannii/nosocomialis:k-mer graph shows possible mixture | |
BD Phoenix TM Automated Microbiology System = BDAMS | ||||
Part (c): Genomic Comparison and MALDI Performance Based on Typing of Five Samples (6276067, 68, 70, 71, 73) | ||||
No. | WGS Code | Name of CROs with BDAMS | Name of CRO After WGS | |
5 | 6276067 | A. baumannii | Acinetobacter seifertii (sensu lato) | |
6 | 6276068 | E. cloacea | Enterobacter cloacae/hormaechei (sensu lato) | |
8 | 6276070 | A. baumannii (sensu lato) | Acinetobacter nosocomialis (sensu stricto) | |
9 | 6276071 | A. baumanni (sensu lato) | Acinetobacter nosocomialis (sensu stricto) | |
11 | 6276073 | A. baumanni (sensu lato) | Acinetobacter baumannii/nosocomialis (assembly shattered, possibly mixture) |
Part (a): The Results of Determining the Contamination/Transmission from 6276067 to 6276073_Isolate by Comparing the Number of Genomes of Samples (from S67 to S73_Isolate) | |||||
---|---|---|---|---|---|
N of Genomes of A. Nosocomialis (1) | N of Genome Different Between (2) | Ratio of Genome Difference (%): (2)/(1) | Ratio of Genome Difference in Two Isolates of the Same Species (%) | Results | |
A. seifertii and S67 | 3,940,614 | 42,246 | 1.07% | <5.00% | S67 is A. seifertii |
A. baumannii and S69 | 3,940,614 | 28,554 | 0.72% | <5.00% | S69 is A. baumannii |
S69 and S72 | 3,940,614 | 27,818 | 0.71% | <5.00% | S72 is A. baumannii |
S71 and S70 | 3,940,614 | 2693 | 0.07% | <5.00% | S73, S71, and S70 belong to an identical clone |
S73 and S70 | 3940614 | 941 | 0.02% | <5.00% | |
S73 and S71 | 3940614 | 1775 | 0.05% | <5.00% | |
S67 = 6276067_isolate, S69 = 6276069_isolate, S70 = 6276070_isolate, S71 = 6276071_isolate, S72 = 6276072_Isolate, S73 = 6276073_isolate | |||||
Part (b): ANI Matrix of Isolates and 2 Public Reference Genomes (A. nosocomialis, A. seifertii) | |||||
OrthoANI values calculated from the OAT software [30] | S70_ | S71_ | S73_ | A. nosocomialis | A. seifertii |
asm (C3022) | asm (C3011) | asm (H009) | |||
S70_asm | |||||
S71_asm | 97.6561 | ||||
S73_asm | 98.8262 | 99.347 | |||
A. nosocomialis | 97.6676 | 97.4891 | 97.8075 | ||
A. seifertii | 91.9344 | 91.8987 | 91.9274 | 92.2549 | |
A. baumanii | 91.5521 | 91.5963 | 91.4095 | 91.363 | 89.7719 |
HCWs (N = 20) | ||||||||
CROs | ||||||||
E. cloacae_(Class B) | 1 | 5% | ||||||
E. coli | 1 | 5% | ||||||
E. coli_(Class B) | 1 | 5% | ||||||
E. coli_(Class D) | 1 | 5% | ||||||
A. baumannii | 2 | 10% | ||||||
Non-CROs | 14 | 70% | ||||||
Residents (N = 67) | ||||||||
CROs | ||||||||
E. coli_(Class D) | 1 | 1.49% | ||||||
A. baumannii | 7 | 10.45% | ||||||
B. cepacia complex | 1 | 1.49% | ||||||
P. aeruginosa | 1 | 1.49% | ||||||
Non-CROs | 57 | 85% | ||||||
† K. pneumoniae (Class D) | ||||||||
†: a child was colonized by E.coli Class D and K. pneumoniae | ||||||||
Environment (N = 175) | ||||||||
CROs | ||||||||
A. baumannii | 8 | 4.57% | ||||||
A. faecalis | 4 | 2.29% | ||||||
P. aeruginosa | 1 | 0.57% | ||||||
P. putida | 4 | 2.29% | ||||||
S. maltophilia | 2 | 1.14% | ||||||
Non-CROs | 156 | 89.14% |
Part (a): Demography Characteristics of HCWs and Residents | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Sex | 2. Age (Years) | 3. Occupation | 4. Seven Days for Work p WK | |||||||||||||||||||||||||||||||||||||
H | Rsd | H | Rsd | H | Rsd | H | Rsd | |||||||||||||||||||||||||||||||||
N, 20 | N, 67 | N, 20 | N, 67 | N, 20 | N, 67 | N, 20 | N, 67 | |||||||||||||||||||||||||||||||||
n, % | n, % | n, % | n, % | n, % | n, % | n, % | n, % | |||||||||||||||||||||||||||||||||
Female | 20 (100) | 18 (26.9) | ≥27 yrs old is cut-point | Cc | 12 (60) | 0 | 20 (100) | 4 (6) | ||||||||||||||||||||||||||||||||
Male | 0 (0) | 49 (73.1) | Min/Max of age | 20.00/66.00 | 4.00/26.00 | Cln | 1 (5) | 0 | 6. N of hrs for PW or W per Day | |||||||||||||||||||||||||||||||
FP | 2 (10) | 0 | 0 | 63 (94.0) | ||||||||||||||||||||||||||||||||||||
5. Drt of PW/Rsd (Years) | ≤20 | 1 (5) | 62 (92.5) | Gd | 1 (5) | 0 | 0.5 | 3 (4.5) | ||||||||||||||||||||||||||||||||
<5 yrs | 10 (50) | 22 (32.84) | >20 | 4 (20) | 5 (7.5) | Mgr of Ct | 1 (5) | 0 | 4 | 1 (1.5) | ||||||||||||||||||||||||||||||
>5 | 3 (15) | 37 (55.22) | > 0. | 5 (25) | Pharm | 1 (5) | 0 | 7 | 2 (10) | |||||||||||||||||||||||||||||||
>10 | 7 (35) | 8 (11.94) | >40 | 10 (50) | RN | 2 (10) | 0 | 8 | 10 (50) | |||||||||||||||||||||||||||||||
No_OCCU | 67 (100) | 10 | 8 (40) | |||||||||||||||||||||||||||||||||||||
Part (b): Demographic characteristics of HCWs and orphan patients to antibiotic use | ||||||||||||||||||||||||||||||||||||||||
7. ABU | 9. N of Ds of ABU for LT BEF St part | 10. LABU, HL, ago (ds): | ||||||||||||||||||||||||||||||||||||||
H | Rsd | H | Rsd | H | Rsd | |||||||||||||||||||||||||||||||||||
N, 20 | N, 67 | N, 20 | N, 67 | N, 20 | N, 67 | |||||||||||||||||||||||||||||||||||
n, % | n, % | n, % | n, % | n, % | n, % | |||||||||||||||||||||||||||||||||||
Yes | 13 (65) | 5 (7.46) | 0 | 7 (35) | 62 (92.5) | 0 (day) | 7 (35) | 62 (92.50) | ||||||||||||||||||||||||||||||||
No | 7 (35) | 62 (92.5) | 1 | 2 (10) | 14 | 3 (15) | 1 (1.50) | |||||||||||||||||||||||||||||||||
8. N of Ts for ABU in LY (times) | 2 to 4 | 4 (20) | 30 | 3 (15) | 1 (1.50) | |||||||||||||||||||||||||||||||||||
0 | 7 (35) | 62 (92.5) | 5 | 4 (20) | 4 (6.0) | 60 | 2 (3.00) | |||||||||||||||||||||||||||||||||
1 to 2 | 5 (25) | 5 (7.5) | 6 to 7 | 2 (10) | 90 | 3 (15) | 1 (1.50) | |||||||||||||||||||||||||||||||||
3 to 4 | 5 (25) | 10 | 1 (1.5) | 120 | 3 (15) | |||||||||||||||||||||||||||||||||||
8 to 10 | 3 (15) | 30 | 1 (5) | 180 | 1 (5) | |||||||||||||||||||||||||||||||||||
11. N of ds for 1st ABU days) | 12. N of days for 2nd ABU | 13. List of AB used for 1st time to treat IDs | ||||||||||||||||||||||||||||||||||||||
2 to 4 | 4 (20) | No_Use | 19 (95) | 63 (94.03) | AMC (2:1) | 2 (10) | 1 (1.49) | |||||||||||||||||||||||||||||||||
5 | 4 (20) | 5 (7.46) | Not RMR | 1 (5) | 1 (1.49) | AMC (2:1) | 3 (15) | AMC, 1 (1.49) | ||||||||||||||||||||||||||||||||
6 to 7 | 2 (10) | Use | 0 | 5 days, 3 (4.48) | AMOX | 1 (5) | AZI, 250 mg: 2 (2.99) | |||||||||||||||||||||||||||||||||
30 | 1 (5) | No use | 7 (35) | 62 (92.54) | ||||||||||||||||||||||||||||||||||||
0 day | 7 (35) | 62 (92.53) | 14. List of AB used for 2nd time to treat IDs | Not RMB | 7 (35) | AZI, 500 mg: 1 (1.49) | ||||||||||||||||||||||||||||||||||
not RMR | 2 (10) | No (Use and RMB) | 20 (100) | 64 (95.52) | ||||||||||||||||||||||||||||||||||||
T of ds for ABU | 75 | 25 | ABU | CPN, 250, 3 (4.48) | ||||||||||||||||||||||||||||||||||||
Part (c): Characteristics related to treating HCWs and residents in and out of the Center of Care and Protection of Orphan Children | ||||||||||||||||||||||||||||||||||||||||
15. N of HA Os of C of C and P of OC | 16. Rs for HA Os of C of C and P of OC | 17. LHA Os of C of C and P of OC, HL ago (Ds) | ||||||||||||||||||||||||||||||||||||||
H | Rsd | H | Rsd | H | Rsd | |||||||||||||||||||||||||||||||||||
N, 20 | N, 67 | N, 20 | N, 67 | N, 20 | N, 67 | |||||||||||||||||||||||||||||||||||
n, % | (n, %) | n, % | (n, %) | n, % | (n, %) | |||||||||||||||||||||||||||||||||||
No_Ad | 17 (85) | 56 (83.6) | KLT | 1 (5) | 10 | 1 (1.49) | ||||||||||||||||||||||||||||||||||
1 | 3 (15) | 3 (4.5) | LF | 1 (5) | 60 | 1 (5) | ||||||||||||||||||||||||||||||||||
2 to 3 | 5 (7.5) | PNA | 1 (5) | 120 | 1 (5) | |||||||||||||||||||||||||||||||||||
Many times | 3 (4.5) | SDU | 1 (1.49) | 365 | 1 (5) | |||||||||||||||||||||||||||||||||||
No_Ad | 17 (85) | 66 (98.51) | No_Ad | 17 (85) | 66 (98.50) | |||||||||||||||||||||||||||||||||||
18. N of Ds for L HA Os of C of C and P of OC | 20. LHA at C of C and P of OC, HL ago (Ds) | 21. Reas for ADM at C of C And P of OC | ||||||||||||||||||||||||||||||||||||||
0 days | 17 (85) | 66 (98.5) | 10:00 | 3 (4.5) | Epilepsy | 3 (4.5) | ||||||||||||||||||||||||||||||||||
4 | 1 (5) | 14 | 1 (1.5) | Flu: | 1 (1.5) | |||||||||||||||||||||||||||||||||||
5 | 2 (10) | 30 | 3 (4.5) | PNA | 3 (4.5) | |||||||||||||||||||||||||||||||||||
10 | 1 (1.5) | 60 | 2 (3.0) | SDU | 1 (1.5) | |||||||||||||||||||||||||||||||||||
19. Chronic Diseases | 90 | 1 (1.5) | SF | 1 (1.5) | ||||||||||||||||||||||||||||||||||||
Yes | 11 (55) | 57 (85.1) | 120 | 1 (1.5) | Sinusitis | 1 (1.5) | ||||||||||||||||||||||||||||||||||
NL | 9 (45) | 10 (14.9) | No HA | 20 (100) | 56 (83.6) | No_Reas | 20 (100) | 57 (85) | ||||||||||||||||||||||||||||||||
Part (d): Characteristics related to chronic diseases in HCWs and residents | ||||||||||||||||||||||||||||||||||||||||
H | Rsd | Rsd | ||||||||||||||||||||||||||||||||||||||
N, 20 | N, 67 | N, 67 | ||||||||||||||||||||||||||||||||||||||
n (%) | n (%) | n (%) | ||||||||||||||||||||||||||||||||||||||
NL | 10 (50) | NL | 10 (14.9) | HPA + SI: | 1 (1.5) | |||||||||||||||||||||||||||||||||||
CTS | 2 (10) | AT | 1 (1.5) | HR + SI: | 2 (3.00) | |||||||||||||||||||||||||||||||||||
DM | 1 (5) | CP | 27 (40.3) | ID | 2 (3.0) | |||||||||||||||||||||||||||||||||||
HND | 1 (5) | CP + VI | 1 (1.5) | OI | 2 (3.0) | |||||||||||||||||||||||||||||||||||
ELE | 1 (5) | CP + ELS | 2 (3.0) | ELS | 5 (7.50) | |||||||||||||||||||||||||||||||||||
HTN | 1 (5) | DS | 6 (9.00) | ELS+ SZR | 1 (1.50) | |||||||||||||||||||||||||||||||||||
LF | 1 (5) | DS + SI | 2 (3.0) | ELS+ ID | 1 (1.5) | |||||||||||||||||||||||||||||||||||
LRG | 1 (5) | ID | 1 (1.5) | |||||||||||||||||||||||||||||||||||||
SD | 1 (5) | HC | 1 (1.5) | |||||||||||||||||||||||||||||||||||||
SDH | 1 (5) | HPA | 2(3.0) | |||||||||||||||||||||||||||||||||||||
Part (e): Characteristics related to procedures performed on HCWs and Children | ||||||||||||||||||||||||||||||||||||||||
22. Past operation before participating in study | 24. Last operation before participating in study, how long ago | 26. Number of days for peripheral intra-catheter use before participating in study | ||||||||||||||||||||||||||||||||||||||
H | Rsd | H | Rsd | H | Rsd | |||||||||||||||||||||||||||||||||||
N, 20 | N, 67 | N, 20 | N, 67 | N, 20 | N, 67 | |||||||||||||||||||||||||||||||||||
n, % | n, % | n, % | n, % | n, % | n, % | |||||||||||||||||||||||||||||||||||
0 (yrs) | 18 (90) | 66 (98.5) | 0 day | 18 (90) | 66 (98.50) | |||||||||||||||||||||||||||||||||||
Yes | 1 (5) | 1 (1.50) | 1 | 2 (10) | 1 | 1 (5) | 1 (1.50) | |||||||||||||||||||||||||||||||||
No | 19 (95) | 66 (98.5) | 6 | 1 (1.50) | 5 | 1 (5) | ||||||||||||||||||||||||||||||||||
23. Number of times for past operations last year before participating in study | 25. Use of peripheral catheter before participating in study | 27. Urinary catheter use before participating in study | ||||||||||||||||||||||||||||||||||||||
0 time | 19 (95) | 66 (98.5) | Yes | 2 (10) | 1 (1.50) | No use | 20 (100) | 67 (100) | ||||||||||||||||||||||||||||||||
1 | 1 (5) | 1 (1.50) | No | 18 (90) | 66 (98.5) |
HCWs + RESIDENTS = 87 | CRO | n_CROs | Pearson χ2 | p Value | Fisher’s Exact Test (2-Sided) | OR | 95% CI | |
---|---|---|---|---|---|---|---|---|
1. HCWs (20) | 6 (3.7) | 14 (16.3) | 2.332 | 0.127 | 0.185 | 2.443 | 0.759 | 7.862 |
RESIDENTS (67) | 10 (12.3) | 57 (54.7) | ||||||
2. AGE ≥ 27 yrs | 6 (3.5) | 13 (15.5) | 2.817 | 0.093 | 0.106 | 2.677 | 0.825 | 8.689 |
/Others | 10 (12.5) | 58 (55.5) | ||||||
3. AGE ≥ 27 yrs and ABU | 2 (2.2) | 10 (9.8) | 0.028 | 0.868 | 1 | 0.871 | 0.172 | 4.428 |
/Others | 14 (13.8) | 61 (61.2) | ||||||
4. AGE ≥ 27 yrs and Work 1st floor | 5 (1.8) | 5 (8.2) | 7.522 | 0.006 | 0.016 | 6 | 1.488 | 24.192 |
Others | 11 (14.2) | 66 (62.8) | ||||||
5. AGE ≥ 27 yrs and Work ≥ 4 years | 5 (2.2) | 7 (9.8) | 5.025 | 0.025 | 0.04 | 4.156 | 1.117 | 15.462 |
Others | 11 (13.8) | 64 (61.2) | ||||||
6. Child carers | 5 (2.2) | 7 (9.8) | 5.025 | 0.025 | 0.04 | 4.156 | 1.117 | 15.462 |
/Others | 11 (13.8) | 64 (61.2) | ||||||
7. Age ≥ 27, work ≥ 1 year, in floor 1 | 5 (1.8) | 5 (8.2) | 7.522 | 0.006 | 0.016 | 6 | 1.488 | 24.192 |
/Others | 11 (14.2) | 66 (62.8) | ||||||
8. Age ≥ 27 years, work ≥ 4 years, work time ≥ 8 h per day | 5 (2.2) | 7 (9.8) | 5.025 | 0.025 | 0.04 | 4.156 | 1.117 | 15.462 |
/Others | 11 (13.8) | 64 (61.2) | ||||||
9. Past surgery before participating in study about one year | 1 (0.4) | 1 (1.6) | 1.363 | 0.243 | 0.336 | 4.667 | 0.276 | 78.869 |
/No past surgery | 15 (15.6) | 70 (69.4) | ||||||
10. Peripheral catheter use before participating in study | 1 (0.4) | 1 (1.6) | 4.825 | 0.028 | 0.086 | 10 | 0.847 | 117.999 |
/No peripheral intra-catheter use | 15 (15.6) | 70 (69.4) | ||||||
11. Child carers worked ≥ 2 years at Center, used AB ≥ 2 times and ≥4 days for each time in last time before participating in study | 2 (0.4) | 0 (1.6) | 9.084 | 0.003 | 0.032 | 6.071 | 3.762 | 9.800 (*) |
/Others | 14 (15.6) | 71 (69.4) | ||||||
HCWs/child carers = 12, Residents = 67 | ||||||||
12. Child carers worked ≥ 4 years at Center, used AB ≥ 2 times and ≥4 days for each time in last time before participating in study | 2 (0.4) | 0 (1.6) | 8.755 | 0.003 | 0.034 | 5.923 | 3.608 | 9.723 (**) |
/Others, | 13 (14.6) | 64 (62.4) |
Residents, N = 67 | CRO | n_CRO | Pearson χ2 | p Value | Fisher’s Exact Test (2-Sided) | OR | 95% C.I | |
---|---|---|---|---|---|---|---|---|
13. Age < 9 years and resided in center ≤ 7.5 years | 3 (9) | 3 (5.1) | 6.385 | 0.012 | 0.039 | 7.714 | 1.296 | 45.905 |
the rest of residents | 7 (9.1) | 54 (51.9) | ||||||
14. Age < 9 years and resided in center ≤ 7.5 years, Times of ABU ≥ 2, ABU in the first time ≥ 5 days | 1 (0.1) | 0 (0.9) | 5.786 | 0.016 | 0.15 | 7.333 | 3.996 | 13.458 |
the rest of residents | 9 (9.9) | 57 (56.1) | ||||||
For cohort CRO = CRO | 6.778 | 1.395 | 32.922 | |||||
Residents, N = 67 | ABU | n_ABU | Pearson χ2 | p value | Fisher’s Exac t Test (2-sided) | OR | 95% C.I | |
15. Age < 9 years and resided in center ≤ 7.5 years | 2 (0.4) | 4 (5.6) | 6.387 | 0.011 | 0.06 | 9.667 | 1.237 | 75.554 |
/the remaining group | 3 (4.6) | 58 (56.4) | ||||||
For cohort = Antibiotic use (ABU) | 6.778 | 1.395 | 32.922 | |||||
Residents, N = 67 | ABU ≥ 5 days in 1st time for ID treatment | ABU < 5 in 1st time for ID treatment | Pearson χ2 | p value | Fisher’s Exact Test (2-sided) | OR | 95% C.I | |
16. Age < 9 years and resided in center ≤ 7.5 years | 2 (0.4) | 3 (4.6) | 6.387 | 0.011 | 0.06 | 9.667 | 1.237 | 75.554 |
/the remaining group | 4 (5.6) | 58 (56.4) | ||||||
For cohort = ABU ≥ 5 days for 1st time for ID treatment | 6.2 | 1.395 | 32.922 | |||||
ID = Infectious disease |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nguyen, V.K.; Noisumdaeng, P.; Ivanovitch, K.; Athan, E.; Croft, L.; Nguyen, P.T.; Nguyen, H.P.P. Roles of Whole-Genome Sequencing in Determining Transmission and Risk Factors Associated with Carbapenem-Resistant Organisms at a Vietnam HealthCare Center of Orphan Children. Microbiol. Res. 2025, 16, 28. https://doi.org/10.3390/microbiolres16010028
Nguyen VK, Noisumdaeng P, Ivanovitch K, Athan E, Croft L, Nguyen PT, Nguyen HPP. Roles of Whole-Genome Sequencing in Determining Transmission and Risk Factors Associated with Carbapenem-Resistant Organisms at a Vietnam HealthCare Center of Orphan Children. Microbiology Research. 2025; 16(1):28. https://doi.org/10.3390/microbiolres16010028
Chicago/Turabian StyleNguyen, Van Kim, Pirom Noisumdaeng, Katiya Ivanovitch, Eugene Athan, Larry Croft, Phuong Toai Nguyen, and Huu Phuc Pham Nguyen. 2025. "Roles of Whole-Genome Sequencing in Determining Transmission and Risk Factors Associated with Carbapenem-Resistant Organisms at a Vietnam HealthCare Center of Orphan Children" Microbiology Research 16, no. 1: 28. https://doi.org/10.3390/microbiolres16010028
APA StyleNguyen, V. K., Noisumdaeng, P., Ivanovitch, K., Athan, E., Croft, L., Nguyen, P. T., & Nguyen, H. P. P. (2025). Roles of Whole-Genome Sequencing in Determining Transmission and Risk Factors Associated with Carbapenem-Resistant Organisms at a Vietnam HealthCare Center of Orphan Children. Microbiology Research, 16(1), 28. https://doi.org/10.3390/microbiolres16010028